Current Rheumatology Reports

, Volume 4, Issue 3, pp 252–256

Update on colchicine and its mechanism of action

  • Yair Molad
Article

Abstract

Colchicine is a unique anti-inflammatory drug with respect to its limited clinical usefulness and its mode of action. Colchicine is mainly indicated for the treatment and prophylaxis of gout and familial Mediterranean fever. Its mode of action includes modulation of chemokine and prostanoid production and inhibition of neutrophil and endothelial cell adhesion molecules by which it interferes with the initiation and amplification of the joint inflammation. This paper discusses its adverse effects and indications.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Hartung EF: History of the use of colchicum and related medicaments in gout. Ann Rheum Dis 1954, 13:190–200.PubMedGoogle Scholar
  2. 2.
    Pelletier PJ, Caventou JB: Examen clinique de plusiers vegetaux de la famille des colchicees et du principe actif qu’ils enferment. Ann Chim Phys 1820, 14:69.Google Scholar
  3. 3.
    Wallace SL, Omokoku B, Ertel NH: Colchicine plasma levels: implications as to pharmacology and mechanism of action. Am J Med 1970, 48:443–448.PubMedCrossRefGoogle Scholar
  4. 4.
    Wallace SL, Ertel NH: Plasma levels of colchicine after oral administration of a single dose. Metabolism 1973, 22:749–753.PubMedCrossRefGoogle Scholar
  5. 5.
    Rochdi M, Sabouraud A, Girre C, et al.: Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects. Eur J Clin Pharmacol 1994, 46:351–354.PubMedCrossRefGoogle Scholar
  6. 6.
    Sabouraud A, Chappey O, Dupin T, Scherrmann JM: Binding of colchicine and thiocolchicoside to human serum proteins and blood cells. Int J Clin Pharmacol Ther 1994, 32:429–432.PubMedGoogle Scholar
  7. 7.
    Ferron GM, Rochdi M, Jusko WJ, Scherrmann JM: Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses. J Clin Pharmacol 1996, 36:874–883.PubMedGoogle Scholar
  8. 8.
    Chappey ON, Niel E, Wautier JL, et al.: Colchicine deposition in human leukocytes after single and multiple oral administration. Clin Pharmacol Ther 1993, 54:360–367.PubMedCrossRefGoogle Scholar
  9. 9.
    Ben-Chetrit E, Scherrmann JM, Zylber-Katz E, Levy M: Colchicine disposition in patients with familial Mediterranean fever with renal impairment. J Rheumatol 1994, 21:710–713.PubMedGoogle Scholar
  10. 10.
    Wallace SL: Colchicine: clinical pharmacology in acute gouty arthritis. Am J Med 1961, 30:439.PubMedCrossRefGoogle Scholar
  11. 11.
    Malawista SE, Bensch KG: Human polymorphonuclear leukocytes: demonstration of microtubules and effect of colchicine. Science 1967, 156:521–522.PubMedCrossRefGoogle Scholar
  12. 12.
    Malawista SE: Colchicine: a common mechanism for its antiinflammatory and anti-mitotic effects. Arthritis Rheum 1968, 11:191–197.PubMedCrossRefGoogle Scholar
  13. 13.
    Bessis M, Breton-Gorius J: Rapports entre noyau et centrioles dans les granulocytes étalalés. Rule des microtubules. Nouvelle Revue Francaise d’Hématologie 1967, 7:601–620.PubMedGoogle Scholar
  14. 14.
    Sackett DL, Varma JK: Molecular mechanism of colchicine action: induced local unfolding of b-tubulin. Biochemistry 1993, 32:13560–13565.PubMedCrossRefGoogle Scholar
  15. 15.
    Van de Candelaere A, Martin SR, Engelborghs Y: Response of microtubules to the addition of colchicine and tubulincolchicine: evaluation of models for the interaction of drugs with microtubules. Biochem J 1997, 323:189–196.Google Scholar
  16. 16.
    Malawista SE: The action of colchicine in acute gouty arthritis. Arthritis Rheum 1975, 18:835–846.PubMedCrossRefGoogle Scholar
  17. 17.
    Landis CL, Haskard DO: Pathogenesis of crystal-induced inflammation. Curr Rheumatol Rep 2001, 3:36–41. This paper summarizes the latest studies on the importance of various inflammatory cells and cytokines in the initiation, amplification, and spontaneous cessation of gout attack.PubMedGoogle Scholar
  18. 18.
    Di Giovine FS, Malawista SE, Thornton E, Duff GW: Urate crystals stimulate production of tumor necrosis factor alfa from human blood monocytes and synovial cells: cytokine mRNA and protein kinetics, and cellular ditribution. J Clin Invest 1991, 87:1375–1381.PubMedGoogle Scholar
  19. 19.
    Roberge CJ, Grassi J, de Medicis R, et al.: Crystal-neutrophil interactions lead to interleukin-1 synthesis. Agents Actions 1991, 34:38–41.PubMedCrossRefGoogle Scholar
  20. 20.
    Li Z, Davis GS, Mohr C, et al.: Inhibition of LPS-induced tumor necrosis factor-a production by colchicine and other microtubules disrupting drugs. Immunobiology 1996, 195:624–639.PubMedGoogle Scholar
  21. 21.
    Ding AH, Porteu F, Sanchez E, Nathan CF: Downregulation of tumor necrosis factor receptors on macrophages and endothelial cells by mictotubule depolarizing agents. J Exp Med 1990, 171:715–727.PubMedCrossRefGoogle Scholar
  22. 22.
    Serhen CN, Lundberg U, Weissmann G, Samuelsson B: Formation of leukotrienes and hydroxy acids from human neutrophils and platelets exposed to monosodium urate. Prostaglandins 1984, 27:503–581.CrossRefGoogle Scholar
  23. 23.
    Reibman J, Haines KA, Rich AM, et al.: Colchicine inhibits ionophor-induced formation of leukotriene B4 by human neutrophils: the role of microtubules. J Immunol 1986, 136:1027–1032.PubMedGoogle Scholar
  24. 24.
    Ehrenfeld M, Levy M, Bar Eli M, et al.: Effect of colchicine on polymorphonuclear leukocyte chemotaxis in human volunteers. Br J Clin Pharmacol 1980, 10:297–300.PubMedGoogle Scholar
  25. 25.
    Hambleton P, Miller P: Pharmacological investigation of acute cellular accumulation in immunological air pouch inflammation. Agents Actions 1989, 28:73–77.PubMedCrossRefGoogle Scholar
  26. 26.
    Liu RU, O’Connell M, Johnson K, et al.: Extracellular signalregulated kinase 1/extracellular signal-regulated kinase 2 mitogen-activated protein kinase signaling and activation of activator protein 1 and nuclear factor _B transcription factors play central roles in interleukin-8 expression stimulated by monosodium urate monohydrate and calcium pyrophosphate crystals in monocytic cells. Arthritis Rheum 2000, 43:1145–1155. This study explores the the intracellular signaling pathways involved in crystal-induced mitogen-activated protein kinase signal transduction and interleukin-8 transcriptional activation in human monocytic cells.PubMedCrossRefGoogle Scholar
  27. 27.
    Gillespie E, Levine RJ, Malawista SE: Histamine release from rat peritoneal mast cells: inhibition by colchicines and potentiation by deuterium oxide. J Pharmacol Exp Ther 1968, 164:158–165.PubMedGoogle Scholar
  28. 28.
    Pouliot M, James MJ, McColl SR, et al.: Monosodium urate microcrystals induce cyclooxygenase-2 in human monocytes. Blood 1998, 91:1769–1776. This paper describes the effect of monosodium urate crystals on monocyte cyclooxygenase-2 and prostanoid production, which is inhibited by colchicine.PubMedGoogle Scholar
  29. 29.
    Fordham JN, Kirwan J, Cason J, Currey HLF: Prolonged reduction in polymorphonuclear adhesion following oral colchicine. Ann Rheum Dis 1981, 40:605–608.PubMedCrossRefGoogle Scholar
  30. 30.
    Asako H, Kubes P, Baethge BA, et al.: Colchicine and methotrexate reduce leukocyte adherence and emigration in rat mesenteric venules. Inflammation 1992, 16:45–56.PubMedCrossRefGoogle Scholar
  31. 31.
    Cronstein BN, Weissmann G: The adhesion molecules of inflammation. Arthritis Rheum 1993, 36:147–157.PubMedGoogle Scholar
  32. 32.
    Cronstein BN, Molad Y, Reibman J, et al.: Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest 1995, 96:994–1002.PubMedGoogle Scholar
  33. 33.
    Paya M, Terencio MC, Ferrandiz ML, Alcaraz MJ: Involvement of secretory phospholipase A2 activity in the zymosan air pouch model of inflammation. Br J Pharmacol 1996, 117:1773–1779.PubMedGoogle Scholar
  34. 34.
    Zurier RB, Hoffstein S, Weissmann G: Mechanisms of lysosomal enzyme release from human leukocytes: I, effect of cyclic nucleotides and colchicine. J Cell Biol 1973, 58:27–41.PubMedCrossRefGoogle Scholar
  35. 35.
    Wright DG, Malawista SE: Mobilization and extracellular release of granular enzymes from human leukocytes during phagocytosis: inhibition by colchicine and cortisol but not by salicylates. Arthritis Rheum 1973, 16:749–758.PubMedCrossRefGoogle Scholar
  36. 36.
    Roberge CJ, Gaudry M, De Medicis R, et al.: Crystal-induced neutrophil activation: IV, specific inhibition of tyrosine phosphorylation by colchicine. J Clin Invest 1993, 92:1722–1729.PubMedGoogle Scholar
  37. 37.
    Roberge CJ, Gaudry M, Gilbert C, et al.: Paradoxical effects of colchicines on the activation of human neutrophils by chemotactic factors and inflammatory micricrystals. J Leukoc Biol 1996, 59:864–871.PubMedGoogle Scholar
  38. 38.
    Peters-Golden M, McNish RW, Davis JA, et al.: Colchicine inhibits arachidonate release and 5-lipoxygenase action in alveolar macrophages. Am J Physiol 1996, 271:L1004-L1013.PubMedGoogle Scholar
  39. 39.
    Mekori YA, Baram D, Goldberg A, Klajman A: Inhibition of delayed hypersensitivity reactions in mice by colchicine. Cell Immunol 1989, 120:330–340.PubMedCrossRefGoogle Scholar
  40. 40.
    Gillespie E, Lichtenstein LM: Histamine release from human leukocytes: studies with deuterium oxide, colchicine and cytochalasine B. J Clin Invest 1972, 51:2941–2947.PubMedGoogle Scholar
  41. 41.
    Malaisse WJ, Malaisse-Lagae F, Van Obbergen E, et al.: Role of microtubules in the phasic pattern of insulin release. Ann NY Acad Sci 1975, 253:630–652.PubMedCrossRefGoogle Scholar
  42. 42.
    Reaven EP, Reaven GM: A quantitative ultrastructural study of microtubule content and secretory granule accumulation in parathyroid glands of phosphate and colchicine treated rats. J Clin Invest 1975, 56:49–55.PubMedGoogle Scholar
  43. 43.
    Bonfoco E, Ceccatelli S, Manzo L, Nicotera P: Colchicine induces apoptosis in cerebellar granule cells. Exp Cell Res 1995, 218:189–200.PubMedCrossRefGoogle Scholar
  44. 44.
    Emmerson BT: The management of gout. N Engl J Med 1996, 334:445–451.PubMedCrossRefGoogle Scholar
  45. 45.
    Ahern MJ, Reid C, Gordon TP, et al.: Does colchicine work? The results of the first controlled study in acute gout. Aust NZ J Med 1987, 17:301–304.Google Scholar
  46. 46.
    Wallace SL, Singer JZ: Review: systemic toxicity associated with the intravenous administration of colchicine-guidelines for use. J Rheumatol 1988, 15:495–499.PubMedGoogle Scholar
  47. 47.
    Roberts WN, Liang MH, Stern SH: Colchicine in acute gout: reassessment of risks and benefits. JAMA 1987, 257:1920–1922.PubMedCrossRefGoogle Scholar
  48. 48.
    Paulus HE, Schlosstein LH, Godfrey RG, et al.: Prophylactic colchicine therapy of intercritical gout: a placebo-controlled study of probenecid-treated patients. Arthritis Rheum 1974, 17:609–614.PubMedCrossRefGoogle Scholar
  49. 49.
    Ben-Chetrit E, Levy M: Colchicine: 1998 update. Semin Arthritis Rheum 1998, 28:48–59. An update on the use of colchicine in familial Mediterranean fever, with detailed description of the drug’s side effects.PubMedCrossRefGoogle Scholar
  50. 50.
    Baud FJ, Sabouraud A, Vicaut E, et al.: Brief report: treatment of severe colchicine overdose with colchicine-specific Fab fragment. N Engl J Med 1995, 332:642–645.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2002

Authors and Affiliations

  • Yair Molad
    • 1
  1. 1.Rabin Medical CenterPetah TikvaIsrael

Personalised recommendations